Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17α-hydroxylase-C17,20-lyase (Cyp17).

Blass BE, Iyer P, Abou-Gharbia M, Childers WE, Gordon JC, Ramanjulu M, Morton G, Arumugam P, Boruwa J, Ellingboe J, Mitra S, Reddy Nimmareddy R, Paliwal S, Rajasekhar J, Shivakumar S, Srivastava P, Tangirala RS, Venkataramanaiah K, Bobbala R, Yanamandra M, Krishnakanth Reddy L.

Bioorg Med Chem Lett. 2018 Jul 15;28(13):2270-2274. doi: 10.1016/j.bmcl.2018.05.040. Epub 2018 May 22.

PMID:
29803730
2.

Design, synthesis, and evaluation of (2S,4R)-Ketoconazole sulfonamide analogs as potential treatments for Metabolic Syndrome.

Blass BE, Iyer P, Abou-Gharbia M, Childers WE, Gordon JC, Ramanjulu M, Morton G, Arumugam P, Boruwa J, Ellingboe J, Mitra S, Nimmareddy RR, Paliwal S, Rajasekhar J, Shivakumar S, Srivastava P, Tangirala RS, Venkataramanaiah K, Yanamandra M.

Bioorg Med Chem Lett. 2016 Dec 1;26(23):5825-5829. doi: 10.1016/j.bmcl.2016.10.016. Epub 2016 Oct 10.

PMID:
27789139
3.

Identification and characterization of acidic mammalian chitinase inhibitors.

Cole DC, Olland AM, Jacob J, Brooks J, Bursavich MG, Czerwinski R, DeClercq C, Johnson M, Joseph-McCarthy D, Ellingboe JW, Lin L, Nowak P, Presman E, Strand J, Tam A, Williams CM, Yao S, Tsao DH, Fitz LJ.

J Med Chem. 2010 Aug 26;53(16):6122-8. doi: 10.1021/jm100533p.

PMID:
20666458
4.

Ion channel screening plates: design, construction, and maintenance.

Mayer SC, Butera JA, Diller DJ, Dunlop J, Ellingboe J, Fan KY, Kaftan E, Mekonnen B, Mobilio D, Paslay J, Tawa G, Vasilyev D, Bowlby MR.

Assay Drug Dev Technol. 2010 Aug;8(4):504-11. doi: 10.1089/adt.2009.0239.

PMID:
20470241
5.

Novel benzofuran derivatives with dual 5-HT1A receptor and serotonin transporter affinity.

Venkatesan AM, Dos Santos O, Ellingboe J, Evrard DA, Harrison BL, Smith DL, Scerni R, Hornby GA, Schechter LE, Andree TH.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):824-7. doi: 10.1016/j.bmcl.2009.12.093. Epub 2010 Jan 4.

PMID:
20064720
6.

Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists.

Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1237-40. doi: 10.1016/j.bmcl.2009.11.122. Epub 2009 Dec 4.

PMID:
20042333
7.

Identification of a new class of small molecule C5a receptor antagonists.

Chen JJ, Cole DC, Ciszewski G, Crouse K, Ellingboe JW, Nowak P, Tawa GJ, Berstein G, Li W.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):662-4. doi: 10.1016/j.bmcl.2009.11.058. Epub 2009 Dec 7.

PMID:
20004096
8.

Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors.

Nowak P, Cole DC, Aulabaugh A, Bard J, Chopra R, Cowling R, Fan KY, Hu B, Jacobsen S, Jani M, Jin G, Lo MC, Malamas MS, Manas ES, Narasimhan R, Reinhart P, Robichaud AJ, Stock JR, Subrath J, Svenson K, Turner J, Wagner E, Zhou P, Ellingboe JW.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):632-5. doi: 10.1016/j.bmcl.2009.11.052. Epub 2009 Nov 20.

PMID:
19959359
9.

Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.

Venkatesan AM, Dehnhardt CM, Chen Z, Santos ED, Dos Santos O, Bursavich M, Gilbert AM, Ellingboe JW, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Gibbons J, Abraham R, Mansour TS.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):653-6. doi: 10.1016/j.bmcl.2009.11.057. Epub 2009 Dec 1.

PMID:
19954970
10.

Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.

Nowak P, Cole DC, Brooijmans N, Bursavich MG, Curran KJ, Ellingboe JW, Gibbons JJ, Hollander I, Hu Y, Kaplan J, Malwitz DJ, Toral-Barza L, Verheijen JC, Zask A, Zhang WG, Yu K.

J Med Chem. 2009 Nov 26;52(22):7081-9. doi: 10.1021/jm9012642.

PMID:
19848404
11.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A.

Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.

12.

Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.

Park K, Gopalsamy A, Aplasca A, Ellingboe JW, Xu W, Zhang Y, Levin JI.

Bioorg Med Chem. 2009 Jun 1;17(11):3857-65. doi: 10.1016/j.bmc.2009.04.033. Epub 2009 Apr 22.

PMID:
19410464
13.

(S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor.

Cole DC, Stock JR, Kreft AF, Antane M, Aschmies SH, Atchison KP, Casebier DS, Comery TA, Diamantidis G, Ellingboe JW, Harrison BL, Hu Y, Jin M, Kubrak DM, Lu P, Mann CW, Martone RL, Moore WJ, Oganesian A, Riddell DR, Sonnenberg-Reines J, Sun SC, Wagner E, Wang Z, Woller KR, Xu Z, Zhou H, Jacobsen JS.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):926-9. doi: 10.1016/j.bmcl.2008.11.116. Epub 2008 Dec 6.

PMID:
19097890
14.

Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.

Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, Atchison K, Chlenov M, Cole DC, Comery T, Diamantidis G, Ellingboe J, Fan K, Galante R, Gonzales C, Ho DM, Hoke ME, Hu Y, Huryn D, Jain U, Jin M, Kremer K, Kubrak D, Lin M, Lu P, Magolda R, Martone R, Moore W, Oganesian A, Pangalos MN, Porte A, Reinhart P, Resnick L, Riddell DR, Sonnenberg-Reines J, Stock JR, Sun SC, Wagner E, Wang T, Woller K, Xu Z, Zaleska MM, Zeldis J, Zhang M, Zhou H, Jacobsen JS.

J Med Chem. 2008 Dec 11;51(23):7348-51. doi: 10.1021/jm801252w.

PMID:
19012391
15.

Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.

Cole DC, Asselin M, Brennan A, Czerwinski R, Ellingboe JW, Fitz L, Greco R, Huang X, Joseph-McCarthy D, Kelly MF, Kirisits M, Lee J, Li Y, Morgan P, Stock JR, Tsao DH, Wissner A, Yang X, Chaudhary D.

J Med Chem. 2008 Oct 9;51(19):5958-63. doi: 10.1021/jm800214a. Epub 2008 Sep 11.

PMID:
18783200
16.

Discovery of a novel series of Notch-sparing gamma-secretase inhibitors.

Kreft A, Harrison B, Aschmies S, Atchison K, Casebier D, Cole DC, Diamantidis G, Ellingboe J, Hauze D, Hu Y, Huryn D, Jin M, Kubrak D, Lu P, Lundquist J, Mann C, Martone R, Moore W, Oganesian A, Porte A, Riddell DR, Sonnenberg-Reines J, Stock JR, Sun SC, Wagner E, Woller K, Xu Z, Zhou H, Steven Jacobsen J.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4232-6. doi: 10.1016/j.bmcl.2008.05.064. Epub 2008 May 20.

PMID:
18556202
17.

Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.

Gopalsamy A, Shi M, Golas J, Vogan E, Jacob J, Johnson M, Lee F, Nilakantan R, Petersen R, Svenson K, Chopra R, Tam MS, Wen Y, Ellingboe J, Arndt K, Boschelli F.

J Med Chem. 2008 Feb 14;51(3):373-5. doi: 10.1021/jm701385c. Epub 2008 Jan 16.

PMID:
18197612
18.

Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets.

Cole DC, Stock JR, Chopra R, Cowling R, Ellingboe JW, Fan KY, Harrison BL, Hu Y, Jacobsen S, Jennings LD, Jin G, Lohse PA, Malamas MS, Manas ES, Moore WJ, O'Donnell MM, Olland AM, Robichaud AJ, Svenson K, Wu J, Wagner E, Bard J.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1063-6. Epub 2007 Dec 10.

PMID:
18162398
19.

Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket.

Jennings LD, Cole DC, Stock JR, Sukhdeo MN, Ellingboe JW, Cowling R, Jin G, Manas ES, Fan KY, Malamas MS, Harrison BL, Jacobsen S, Chopra R, Lohse PA, Moore WJ, O'Donnell MM, Hu Y, Robichaud AJ, Turner MJ, Wagner E, Bard J.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):767-71. Epub 2007 Nov 17.

PMID:
18068983
20.

Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.

Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Boikess S, Coupet J, Smith DL, Leung L, Zhang GM, Feng X, Kelly MF, Galante R, Huang P, Dawson LA, Marquis K, Rosenzweig-Lipson S, Beyer CE, Schechter LE.

J Med Chem. 2007 Nov 15;50(23):5535-8. Epub 2007 Oct 19.

PMID:
17948978
21.

Acylguanidines as small-molecule beta-secretase inhibitors.

Cole DC, Manas ES, Stock JR, Condon JS, Jennings LD, Aulabaugh A, Chopra R, Cowling R, Ellingboe JW, Fan KY, Harrison BL, Hu Y, Jacobsen S, Jin G, Lin L, Lovering FE, Malamas MS, Stahl ML, Strand J, Sukhdeo MN, Svenson K, Turner MJ, Wagner E, Wu J, Zhou P, Bard J.

J Med Chem. 2006 Oct 19;49(21):6158-61.

PMID:
17034121
22.

Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site.

Gopalsamy A, Chopra R, Lim K, Ciszewski G, Shi M, Curran KJ, Sukits SF, Svenson K, Bard J, Ellingboe JW, Agarwal A, Krishnamurthy G, Howe AY, Orlowski M, Feld B, O'Connell J, Mansour TS.

J Med Chem. 2006 Jun 1;49(11):3052-5.

PMID:
16722622
23.

1,2,4-Oxadiazolidin-3,5-diones and 1,3,5-triazin-2,4,6-triones as cytosolic phospholipase A2alpha inhibitors.

Gopalsamy A, Yang H, Ellingboe JW, McKew JC, Tam S, Joseph-McCarthy D, Zhang W, Shen M, Clark JD.

Bioorg Med Chem Lett. 2006 Jun 1;16(11):2978-81. Epub 2006 Mar 20.

PMID:
16545564
24.

Design and synthesis of 2,3,4,9-tetrahydro-1H-carbazole and 1,2,3,4-tetrahydro-cyclopenta[b]indole derivatives as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.

Gopalsamy A, Shi M, Ciszewski G, Park K, Ellingboe JW, Orlowski M, Feld B, Howe AY.

Bioorg Med Chem Lett. 2006 May 1;16(9):2532-4. Epub 2006 Feb 15.

PMID:
16480869
25.

Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase.

Gopalsamy A, Aplasca A, Ciszewski G, Park K, Ellingboe JW, Orlowski M, Feld B, Howe AY.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):457-60. Epub 2005 Nov 7.

PMID:
16274990
26.

Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists.

Cole DC, Lennox WJ, Stock JR, Ellingboe JW, Mazandarani H, Smith DL, Zhang G, Tawa GJ, Schechter LE.

Bioorg Med Chem Lett. 2005 Nov 1;15(21):4780-5.

PMID:
16125933
27.

Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel anti-proliferative agents: parallel synthesis for lead optimization of amide region.

Gopalsamy A, Yang H, Ellingboe JW, Tsou HR, Zhang N, Honores E, Powell D, Miranda M, McGinnis JP, Rabindran SK.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1591-4.

PMID:
15745803
28.

Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.

Cole DC, Lennox WJ, Lombardi S, Ellingboe JW, Bernotas RC, Tawa GJ, Mazandarani H, Smith DL, Zhang G, Coupet J, Schechter LE.

J Med Chem. 2005 Jan 27;48(2):353-6.

PMID:
15658848
29.

N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists.

Cole DC, Ellingboe JW, Lennox WJ, Mazandarani H, Smith DL, Stock JR, Zhang G, Zhou P, Schechter LE.

Bioorg Med Chem Lett. 2005 Jan 17;15(2):379-83.

PMID:
15603958
30.

Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors.

Gopalsamy A, Lim K, Ciszewski G, Park K, Ellingboe JW, Bloom J, Insaf S, Upeslacis J, Mansour TS, Krishnamurthy G, Damarla M, Pyatski Y, Ho D, Howe AY, Orlowski M, Feld B, O'Connell J.

J Med Chem. 2004 Dec 16;47(26):6603-8.

PMID:
15588095
31.

Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.

Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JI, Ellingboe J, Skotnicki JS, Dijoseph JF, Sung A, Jin G, Xu W, McCarthy DJ, Barone D.

J Med Chem. 2004 Dec 2;47(25):6255-69.

PMID:
15566296
32.

Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase.

Howe AY, Bloom J, Baldick CJ, Benetatos CA, Cheng H, Christensen JS, Chunduru SK, Coburn GA, Feld B, Gopalsamy A, Gorczyca WP, Herrmann S, Johann S, Jiang X, Kimberland ML, Krisnamurthy G, Olson M, Orlowski M, Swanberg S, Thompson I, Thorn M, Del Vecchio A, Young DC, van Zeijl M, Ellingboe JW, Upeslacis J, Collett M, Mansour TS, O'Connell JF.

Antimicrob Agents Chemother. 2004 Dec;48(12):4813-21.

33.

Identification of [(naphthalene-1-carbonyl)-amino]-acetic acid derivatives as nonnucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase.

Gopalsamy A, Lim K, Ellingboe JW, Krishnamurthy G, Orlowski M, Feld B, van Zeijl M, Howe AY.

Bioorg Med Chem Lett. 2004 Aug 16;14(16):4221-4.

PMID:
15261274
34.

Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1.

Gopalsamy A, Kincaid SL, Ellingboe JW, Groeling TM, Antrilli TM, Krishnamurthy G, Aulabaugh A, Friedrichs GS, Crandall DL.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3477-80.

PMID:
15177456
35.

Synthesis and SAR of bis-statine based peptides as BACE 1 inhibitors.

Hu B, Fan KY, Bridges K, Chopra R, Lovering F, Cole D, Zhou P, Ellingboe J, Jin G, Cowling R, Bard J.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3457-60.

PMID:
15177452
36.

Design and syntheses of 1,6-naphthalene derivatives as selective HCMV protease inhibitors.

Gopalsamy A, Lim K, Ellingboe JW, Mitsner B, Nikitenko A, Upeslacis J, Mansour TS, Olson MW, Bebernitz GA, Grinberg D, Feld B, Moy FJ, O'Connell J.

J Med Chem. 2004 Apr 8;47(8):1893-9.

PMID:
15055990
37.

Use of design of experiments to optimize high-throughput semipreparative LC and LC/MS methods.

Cole DC, Pagano N, Kelly MF, Ellingboe J.

J Comb Chem. 2004 Jan-Feb;6(1):78-82.

PMID:
14714988
38.

Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.

Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, Levin JI, Sandanayaka VP, Du M, Skotnicki JS, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R, Tillett J, Zhao W, McDevitt J, Xu ZB.

J Med Chem. 2003 Jun 5;46(12):2376-96.

PMID:
12773042
39.

Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.

Aranapakam V, Grosu GT, Davis JM, Hu B, Ellingboe J, Baker JL, Skotnicki JS, Zask A, DiJoseph JF, Sung A, Sharr MA, Killar LM, Walter T, Jin G, Cowling R.

J Med Chem. 2003 Jun 5;46(12):2361-75.

PMID:
12773041
40.

Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers.

Gilbert AM, Caltabiano S, Koehn FE, Chen ZJ, Francisco GD, Ellingboe JW, Kharode Y, Mangine A, Francis R, TrailSmith M, Gralnick D.

J Med Chem. 2002 May 23;45(11):2342-5.

PMID:
12014973
41.

Novel (4-piperidin-1-yl)-phenyl sulfonamides as potent and selective human beta(3) agonists.

Hu B, Ellingboe J, Han S, Largis E, Lim K, Malamas M, Mulvey R, Niu C, Oliphant A, Pelletier J, Singanallore T, Sum FW, Tillett J, Wong V.

Bioorg Med Chem. 2001 Aug;9(8):2045-59.

PMID:
11504641
42.

New oxadiazolidinedione derivatives as potent and selective human beta3 agonists.

Hu B, Malamas M, Ellingboe J, Largis E, Han S, Mulvey R, Tillett J.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):981-4.

PMID:
11327605
43.

(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists.

Hu B, Ellingboe J, Han S, Largis E, Mulvey R, Oliphant A, Sum FW, Tillett J.

J Med Chem. 2001 Apr 26;44(9):1456-66.

PMID:
11311069
44.

2,4-Thiazolidinediones as potent and selective human beta3 agonists.

Hu B, Ellingboe J, Gunawan I, Han S, Largis E, Li Z, Malamas M, Mulvey R, Oliphant A, Sum FW, Tillett J, Wong V.

Bioorg Med Chem Lett. 2001 Mar 26;11(6):757-60.

PMID:
11277513
45.

Parallel solid-phase synthesis of vitronectin receptor (alphavbeta3) inhibitors.

Gopalsamy A, Yang H, Ellingboe JW, Kees KL, Yoon J, Murrills R.

Bioorg Med Chem Lett. 2000 Aug 7;10(15):1715-8.

PMID:
10937731
46.

Novel and selective calcitonin-inducing agents.

Gilbert AM, Caltabiano S, Roberts D, Sum SF, Francisco GD, Lim K, Asselin M, Ellingboe JW, Kharode Y, Cannistraci A, Francis R, TrailSmith M, Gralnick D.

J Med Chem. 2000 Mar 23;43(6):1223-33.

PMID:
10737755
47.

Prodrugs of CL316243: a selective beta3-adrenergic receptor agonist for treating obesity and diabetes.

Sum FW, Gilbert A, Venkatesan AM, Lim K, Wong V, O'Dell M, Francisco G, Chen Z, Grosu G, Baker J, Ellingboe J, Malamas M, Gunawan I, Primeau J, Largis E, Steiner K.

Bioorg Med Chem Lett. 1999 Jul 19;9(14):1921-6.

PMID:
10450954
48.

Solid-phase synthesis in lead optimization and drug discovery.

Ellingboe JW.

Curr Opin Drug Discov Devel. 1999 Jul;2(4):350-7.

PMID:
19649963
49.

Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group.

Ellingboe JW, Collini MD, Quagliato D, Chen J, Antane M, Schmid J, Hartupee D, White V, Park CH, Tanikella T, Bagli JF.

J Med Chem. 1998 Oct 22;41(22):4251-60.

PMID:
9784100
50.

Effects of aporphine isomers on rat prolactin.

Baldessarini RJ, Campbell A, Ben-Jonathan N, Ellingboe J, Zong R, Neumeyer JL.

Neurosci Lett. 1994 Aug 1;176(2):269-71.

PMID:
7830962

Supplemental Content

Loading ...
Support Center